# ALPS Medical Breakthroughs ETF (0H6M)

**Page:** https://fundology.uk/fund/0h6m · ISIN US00162Q5936

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 20/11/2026, 0H6M (ALPS Medical Breakthroughs ETF, ISIN US00162Q5936) closed at $57.34 on the London Stock Exchange. Its ongoing charge is 0.50% a year (about £50 on £10,000). Over the five years to 20/11/2026 its total return was +28.5%, or +0.8% after UK CPIH inflation.

## Summary

ALPS Medical Breakthroughs ETF is an exchange-traded fund (ETF) from ALPS, launched in 2014. It tracks the S-Network Medical Breakthroughs Index. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.5% a year — about £50 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is paid out to holders as cash.

> This fund is domiciled outside the UK and EU and does not publish the key information document UK rules require, so most UK platforms do not offer it to retail investors. It is shown for reference.

Latest close: **$57.34** (20/11/2026). The close has not changed since 12/11/2026; this line may not have traded since then.

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | 0H6M |
| ISIN | US00162Q5936 |
| Category | Healthcare |
| Type | ETF |
| Provider | ALPS |
| Tracks | S-Network Medical Breakthroughs Index |
| Income | Distributing |
| Ongoing charge | 0.50% a year (£50 per £10,000) |
| Fund size | £135m |
| Launched | 2014 |
| Domicile | United States |

## Past returns (periods to 20/11/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +28.96% | +24.41% | income reinvested |
| 3 years | +137.64% | +113.98% | income reinvested |
| 5 years | +28.54% | +0.81% | income reinvested |

Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 40.23% | -23.23% |

## Charges compared with similar funds

Ongoing charge of ALPS Medical Breakthroughs ETF 0.50% a year. Compared on 21/11/2026, 4 of the 29 other healthcare funds charge more, 1 the same and 24 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.50%** per year (as of 20/11/2026)
- Stocks and shares ISA eligible: no (not generally available to UK retail investors)
- SIPP eligible: no (not generally available to UK retail investors)
- ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify.

## Questions people ask

**What is the ongoing charge of 0H6M?**

The ongoing charge of 0H6M is 0.50% a year — about £50 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of ALPS Medical Breakthroughs ETF 0.50% a year. Compared on 21/11/2026, 4 of the 29 other healthcare funds charge more, 1 the same and 24 less (share classes counted once).

**What does 0H6M track?**

0H6M tracks the S-Network Medical Breakthroughs Index.

**Is 0H6M accumulating or distributing?**

0H6M is distributing: income is paid out to holders as cash. It pays out once a year.

**What is the ISIN of 0H6M?**

The ISIN of 0H6M is US00162Q5936. An ISIN identifies one exact share class of a fund; 0H6M is its ticker on the London Stock Exchange.

**How has 0H6M done after inflation?**

Over the five years to 20/11/2026 0H6M’s total return was +28.5%, or +0.8% after UK CPIH inflation. Past performance is not a guide to future returns.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.
